Limosilactobacillus fermentum role in combination with human mesenchymal stem cell-derived secretome: A novel approach to alleviate inflammation in NASH pathogenesis
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.114686 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Seyedeh Kosar Mahmoudi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Microbial Biotechnology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Limosilactobacillus fermentum, Non-alcoholic Fatty Liver Disease, Secretome. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 65 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Nonalcoholic steatohepatitis (NASH) is caused by the accumulation of excess fat in the liver, chronic inflammation, and cell death. The role of the secretome derived from Wharton's jelly and mesenchymal stem cells (WJ-MSC) in reducing inflammation and apoptosis has been investigated in several studies. Also, the strain Limosilactobacillus fermentum (L.fermentum) was identified as an antimicrobial and antioxidant probiotic. This study looked into the role of a combination of secretome and L.fermentum on cellular stress, apoptosis, and inflammation-related pathways in an NASH in-vitro model. METHODS: Oil Red O staining confirmed the NASH model was induced using oleic acid and palmitic acid. Then, the 3 different groups were treated with two concentrations of WJ-MSCs-derived secretome, cell-free extract (CFE) of L.fermentum, and their combination. Oxidative stress was evaluated, and western blotting was used to identify the protein. Gene expression and protein quantity were assessed using real-time PCR and ELISA. RESULT: The analysis revealed the secretome, L.fermentum, and their combination decreased oxidative stress. Additionally, the low levels of Caspase 3 and 9 led to a reduction in apoptosis. The combined treatment significantly impacted inflammation by increasing IL-10 and decreasing IL-6. The expression of STAT3 was also confirmed to be reduced using western blotting. Despite the significant modulation of TNF-alpha and STAT3 by L. fermentum at a high dose, the combined approach led to enhanced performance and restored the cell proliferation. CONCLUSION: This enhancement has the potential to substantially influence the treatment of NASH disease by impacting inflammation, apoptosis, and oxidative stress, thereby revealing therapeutic potential for NASH disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Microbial Biotechnology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran.
- Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Gastroenterology…
Zitieren
APA
Mahmoudi, S. K., Abdolahi, S., Saniee, P., Zali, M. R., Hatami, B., & Baghaei, K. (2025). Limosilactobacillus fermentum role in combination with human mesenchymal stem cell-derived secretome: A novel approach to alleviate inflammation in NASH pathogenesis. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.114686
Vancouver
Mahmoudi SK, Abdolahi S, Saniee P, Zali MR, Hatami B, Baghaei K. Limosilactobacillus fermentum role in combination with human mesenchymal stem cell-derived secretome: A novel approach to alleviate inflammation in NASH pathogenesis. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.114686
BibTeX
@article{Mahmoudi2025,
author = {Mahmoudi, Seyedeh Kosar and Abdolahi, Shahrokh and Saniee, Parastoo and Zali, Mohammad Reza and Hatami, Behzad and Baghaei, Kaveh},
title = {Limosilactobacillus fermentum role in combination with human mesenchymal stem cell-derived secretome: A novel approach to alleviate inflammation in NASH pathogenesis},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.114686}
}
EUVIMED